New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
10:37 EDTAERISummer Street chief scientific officer holds an analyst/industry conference call
Chief Scientific Officer Classen discusses Aerie Pharmaceuticals' Roclatan for treatment of Glaucoma on an Analyst/Industry conference call to be held on June 12 at 11 am.
News For AERI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 24, 2015
07:31 EDTAERIRBC Capital to hold a conference
Subscribe for More Information
February 18, 2015
06:04 EDTAERIAerie Pharmaceuticals' Rhopressa shows positive preliminary evidence in glaucoma
Aerie Pharmaceuticals announced potentially breakthrough findings from new preclinical research indicating that Aerie’s lead drug candidate, Rhopressa, may block the effect of fibrosis-promoting proteins on cells of the trabecular meshwork, a tissue that helps maintain normal pressure in the eye. Fibrosis at the trabecular meshwork is associated with elevated intraocular pressure in patients with glaucoma. This is the first study to show that Rhopressa, a novel once-daily, triple-action eye drop that lowers IOP in glaucoma patients, has the potential to modify the course of the disease by arresting fibrosis. Pending successful advancement of the Phase 3 registration studies, three-month efficacy results are expected in the middle of Q2. If the trials are successful, the company expects to submit a New Drug Application filing by mid-2016.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use